Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Longboard Pharmaceuticals Inc (NQ: LBPH )

22.81 +0.85 (+3.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 293,870
Open 22.04
Bid (Size) 21.00 (30)
Ask (Size) 25.60 (5)
Prev. Close 21.96
Today's Range 21.46 - 23.16
52wk Range 3.600 - 28.15
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
From Longboard Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-9.12%
-9.12%
1 Month
+8.36%
+8.36%
3 Month
+7.39%
+7.39%
6 Month
+325.56%
+325.56%
1 Year
+186.92%
+186.92%

More News

Read More
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Recap: Longboard Pharmaceuticals Q4 Earnings
Via Benzinga
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Looking Into Longboard Pharmaceuticals's Recent Short Interest
Via Benzinga
Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Forget the "Magnificent Seven" -- This Stock Has Nearly Quadrupled in 2024, and Wall Street Thinks It Can Go a Lot Higher
Via The Motley Fool
Cantor Fitzgerald Maintains Overweight Rating for Longboard Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Longboard Pharmaceuticals, Inc.
Via Business Wire
This biotech stock has surged over 300% this week
Via MarketBeat
Jim Cramer: This Energy Firm Has 'Good Growth, Good Yield' But As For IonQ? Ixnay
Via Benzinga
Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Why Longboard Pharmaceuticals Stock Is Falling
Via Benzinga
Apple, Longboard Pharmaceuticals, Coinbase, Moderna, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
Why Longboard Pharma Catapulted 316%, Leading A Biotech Stock Rally
Via Investor's Business Daily
Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Crude Oil Down 2%; Tesla Deliveries Top Estimates
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
Via Benzinga
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Is Longboard Pharmaceuticals (LBPH) Stock Up 175% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.